In adolescents with poorly controlled moderate to severe atopic dermatitis (AD), treatment with dupilumab significantly improved signs and symptoms of AD, including pruritus and sleep loss, as well as quality of life with an "acceptable" safety profile in a phase 3 study.

A database analysis of more than 300,000 individuals concludes there is no increased risk for adverse cardiovascular events associated with the use of stimulant medications by children and youth with autism.